# Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/pediatric-rare-diseases-a-collaborative-approach-for-drug-development-using-gaucher-disease-as-a-model-draft-guidance-for-industry-draft-guidance-for-industry/b1c7a136-55e0-4a98-90c5-8addb1b9544b

> FDA guidance document: Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry. Issue date: December 07, 2017. Get complete insights and analysis.

---

## Details

- Title: Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2017-12-07
- Comment Close Date: 2018-03-06
- Last Changed: 2024-04-11
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-N-6476">FDA-2017-N-6476</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [Labeling for Combined Hormonal Contraceptives Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/labeling-for-combined-hormonal-contraceptives-guidance-for-industry/551e37b0-1741-4094-9133-77fbce2ceb68)
- [Refuse to File: NDA and BLA Submissions to CDER Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/refuse-to-file-nda-and-bla-submissions-to-cder-guidance-for-industry/9d29f151-eed6-4c49-afde-4bcd7fa65bf7)